Macrocyclic Versions of Natural Antimicrobial Peptides: Broad-Spectrum Antibiotics That Resist Bacterial Defenses
Macrocyclic hairpin mimetics of the antimicrobial peptide protegrin I showed broad-spectrum antibiotic activity including against drug-resistant bacteria, with improved stability over linear peptide antibiotics.
Quick Facts
What This Study Found
Macrocyclic hairpin mimetics of protegrin I demonstrated broad-spectrum antibacterial activity including against resistant strains, with improved stability over linear peptide antibiotics and activity maintained in challenging conditions.
Key Numbers
How They Did This
In-vitro antimicrobial study. Macrocyclic protegrin analogs synthesized and tested against panels of gram-positive and gram-negative bacteria, including resistant strains. Activity in serum and salt conditions assessed.
Why This Research Matters
Antibiotic resistance is a global health emergency. Converting natural antimicrobial peptides into stable macrocyclic drugs could generate urgently needed new antibiotic classes.
The Bigger Picture
Natural antimicrobial peptides are effective but unstable. Making them macrocyclic preserves activity while dramatically improving drug properties — a general strategy for the entire antimicrobial peptide field.
What This Study Doesn't Tell Us
In-vitro activity. In-vivo efficacy, pharmacokinetics, and toxicity not assessed. Cost of macrocyclic peptide manufacturing may limit clinical development.
Questions This Raises
- ?Can macrocyclic protegrin analogs treat systemic bacterial infections?
- ?What is the toxicity profile of these compounds?
- ?Could this approach be applied to other antimicrobial peptide families?
Trust & Context
- Key Stat:
- Broad-spectrum + stable Macrocyclic protegrin analogs killed resistant bacteria AND maintained activity in challenging conditions — addressing both efficacy and stability
- Evidence Grade:
- Preliminary in-vitro evidence with broad-spectrum activity data and stability assessment, demonstrating a viable new antibiotic approach.
- Study Age:
- Published in 2002. Macrocyclic antimicrobial peptide mimetics have advanced significantly, with some entering clinical development.
- Original Title:
- Macrocyclic hairpin mimetics of the cationic antimicrobial peptide protegrin I: a new family of broad-spectrum antibiotics.
- Published In:
- Chembiochem : a European journal of chemical biology, 3(11), 1126-33 (2002)
- Authors:
- Shankaramma, Sasalu C, Athanassiou, Zafiria, Zerbe, Oliver, Moehle, Kerstin, Mouton, Carole, Bernardini, Francesca, Vrijbloed, Jan W, Obrecht, Daniel, Robinson, John A
- Database ID:
- RPEP-00768
Evidence Hierarchy
Frequently Asked Questions
Can we make better antibiotics from natural peptides?
Yes. This study shows converting natural antimicrobial peptides into ring-shaped (macrocyclic) versions preserves their bacteria-killing ability while making them more stable and drug-like.
Do these work against superbugs?
In lab tests, yes — they killed drug-resistant bacteria. Because they work by disrupting bacterial membranes (a fundamental mechanism), bacteria have difficulty developing resistance to them.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00768APA
Shankaramma, Sasalu C; Athanassiou, Zafiria; Zerbe, Oliver; Moehle, Kerstin; Mouton, Carole; Bernardini, Francesca; Vrijbloed, Jan W; Obrecht, Daniel; Robinson, John A. (2002). Macrocyclic hairpin mimetics of the cationic antimicrobial peptide protegrin I: a new family of broad-spectrum antibiotics.. Chembiochem : a European journal of chemical biology, 3(11), 1126-33.
MLA
Shankaramma, Sasalu C, et al. "Macrocyclic hairpin mimetics of the cationic antimicrobial peptide protegrin I: a new family of broad-spectrum antibiotics.." Chembiochem : a European journal of chemical biology, 2002.
RethinkPeptides
RethinkPeptides Research Database. "Macrocyclic hairpin mimetics of the cationic antimicrobial p..." RPEP-00768. Retrieved from https://rethinkpeptides.com/research/shankaramma-2002-macrocyclic-hairpin-mimetics-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.